https://www.targetedonc.com/view/discussing-phase-1-findings-of-ubamatamab-in-the-ovarian-cancer-space
0
0
1/28/23 at 4:03am
Organization
Targetedonc.com
42 words
0
Comments
David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.
You are the first to view
Create an account
or login to join the discussion